12:00 PM - 12:15 PM (EDT), Thursday, June 8, 2023 ・ Session Room 103
FivepHusion is an advanced clinical stage biotech company developing Deflexifol™, a novel enhanced drug formulation designed to address the safety and efficacy limitations of standard of care chemotherapy for the treatment of solid tumors with significant unmet medical need.

Deflexifol™ combines the chemotherapeutic drug 5-fluorouracil (5-FU) and its biomodulator leucovorin, which improves the anti-tumor activity of 5-FU. These drugs are commonly used globally to treat various solid tumors including colorectal, pancreatic and gastric cancers. The Deflexifol™ all-in-one formulation delivers both agents simultaneously at a physiological pH, thereby improving their safety, tolerability, and anti-tumor activity.

FivepHusion’s strategy is to develop Deflexifol™ via the 505(b)(2) pathway as the new Gold Standard of Care™ for solid tumor treatment, with a planned global phase III pivotal trial in 1st line mCRC to commence in 2024.
Not Provided
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
New South Wales
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Deflexifol™, a novel advanced clinical-stage drug reformulation that enhances chemotherapy for a range of adult and childhood cancers with significant unmet medical need.
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CEO & Managing Director